Phase II trial evaluating the combination of eribulin (E)+ bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study

Hardy-Bessard, A-C.; Brocard, Fabien; Leheurteur, Marianne; Mélis, Adrien; Dauba, Jérôme; Lortholary, Alain; You, Benoît; Guardiola, Emmanuel; Grenier, Julien; Martin-Babau, J.; Meunier, Jérôme; Follana, Philippe; Savoye, Aude Marie; Mercier-Blas, A.; Martí, Alejandro; Despax, Raymond; Barbier, Nicolas; Gane, N. F. C.; Ardisson, P.; Segura-Djezzar, Carine

doi:10.1093/annonc/mdw365.14

Search citation statements

Order By: Relevance

Paper Sections

Select...

ключевые слова: диссеминированный рак молочной железы эрибулин1

Citation Types

Supporting

Mentioning

Contrasting

Unclassified

Year Published

2017

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Комбинация эрибулина с бевацизумабом позволила достичь ЧОО в 46 % случаях, 1-летней ВБП -в 32 % случаях, медианы ВБП -8,3 меся-ца (95 % ДИ 7,0-9,6). Из нежелательных явлений данной комбинации надо отметить нейтропению 3-4 степени в 26 % случаев, периферическую полинейропатию 3-4 сте-пени у 7 % больных [14].…”

Section: ключевые слова: диссеминированный рак молочной железы эрибулинunclassified

Resolution of the Advisory board “Prospects for study and use of eribulin in advanced breast cancer”

Артамонова¹,

Болотина²,

Gorbunova³

et al. 2017

Zlokač. opuholi

View full text Add to dashboard Cite

Section: ключевые слова: диссеминированный рак молочной железы эрибулинunclassified

Resolution of the Advisory board “Prospects for study and use of eribulin in advanced breast cancer”

Артамонова¹,

Болотина²,

Gorbunova³

et al. 2017

Zlokač. opuholi

View full text Add to dashboard Cite

Phase II trial evaluating the combination of eribulin (E)+ bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study

Cited by 1 publication

References 0 publications

Resolution of the Advisory board “Prospects for study and use of eribulin in advanced breast cancer”

Resolution of the Advisory board “Prospects for study and use of eribulin in advanced breast cancer”

Contact Info

Product

Resources

About